1.Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infectious Disease Clinics of North America 1997; 11: 551–581.
2.Russo TA, Johnson JR. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes and Infection 2003; 5: 449–456.
3.Stamm WE, Hooten TM. Management of urinary tract infections in adults. New England Journal of Medicine 1993; 329: 1328–1334.
4.Foxman B, et al. Urinary tract infections: self-reported incidence and associated costs. Annals of Epidemiology 2000; 10: 509–515.
5.Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. American Journal of Medicine 2002; 113 (Suppl. 1A): 5S–13S.
6.Yamamoto S, et al. Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli. Journal of Urology 1997; 157: 1127–1129.
7.Gruneberg RN. Relationship of infecting urinary organism to the fecal flora in patients with symptomatic urinary infection. Lancet 1969; 2: 766–768.
8.Hooton TM, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. New England Journal of Medicine 1996; 335: 468–474.
9.Brown PD, Foxman B. Pathogenesis of urinary tract infection: the role of sexual behavior and sexual transmission. Current Infectious Disease Reports 2000; 2: 513–517.
10.Foxman B, Frerichs RR. Epidemiology of urinary tract infection: I. Diaphragm use and sexual intercourse. American Journal of Public Health 1985; 75: 1308–1313.
11.Kelsey MC, et al. Relationship between sexual intercourse and urinary-tract infection in women attending a clinic for sexually transmitted diseases. Journal of Medical Microbiology 1979; 12: 511–512.
12.Shrikhande SN, Chande CA, Pathak AA. Virulence factors in uropathogenic E. coli. Indian Journal of Pathology and Microbiology 1999; 42: 321–325.
13.Phillips I, et al. Epidemic multiresistant Escherichia coli infection in West Lambeth Health District. Lancet 1988; 1: 1038–1041.
14.Pitout JDD, et al. Community-wide outbreaks of clonally related CTX-M-14 β-lactamase-producing Escherichia coli strains in the Calgary Health Region. Journal of Clinical Microbiology 2005; 43: 2844–2849.
15.Olesen B, et al. Cluster of multiresistant Escherichia coli O78:H10 in Greater Copenhagen. Scandinavian Journal of Infectious Diseases 1994; 26: 406–410.
16.Manges AR, et al. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. New England Journal of Medicine 2001; 345: 1007–1013.
17.Johnson JR, et al. A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis. Lancet 2002; 359: 2249–2251.
18.Manges AR, Dietrich PS, Riley LW. Multidrug-resistant Escherichia coli clonal groups causing community-acquired pyelonephritis. Clinical Infectious Diseases 2004; 38: 329–334.
19.Manges AR, et al. Multidrug-resistant Escherichia coli clonal groups causing community-acquired bloodstream infections. Journal of Infection 2006; 53: 25–29.
20.Aarestrup FM, et al. Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal Enterococci from food animals in Denmark. Antimicrobial Agents and Chemotherapy 2001; 45: 2054–2059.
21.Johnson JR, et al. Antimicrobial-resistant and extraintestinal pathogenic Escherichia coli in retail foods. Journal of Infectious Diseases 2005; 191: 1040–1049.
22.Johnson JR, et al. Contamination of retail foods, particularly turkey, from community markets (Minnesota, 1999–2000) with antimicrobial-resistant and extraintestinal pathogenic Escherichia coli. Foodborne Pathogens and Disease 2005; 2: 38–49.
23.Schroeder CM, et al. Isolation of antimicrobial-resistant Escherichia coli from retail meats purchased in Greater Washington, DC, USA. International Journal of Food Microbiology 2003; 85: 197–202.
24.Vincent C, et al. Food reservoir for Escherichia coli causing urinary tract infections. Emerging Infectious Diseases 2010; 16: 88–95.
25.Wright ED, Perinpanayagam RM. Multiresistant invasive Escherichia coli infection in south London. Lancet 1987; 1: 556–557.
26.Waghorn DJ, Kelly TW, Gibbins W. Epidemic multi-resistant Escherichia coli infection in south London. Journal of Hospital Infection 1988; 11: 192–193.
27.Prats G, et al. Escherichia coli serotype O15:K52:H1 as a uropathogenic clone. Journal of Clinical Microbiology 2000; 38: 201–209.
28.Kunin CM, et al. Isolation of a nicotinamide-requiring clone of Escherichia coli O18:K1:H7 from women with acute cystitis: resemblance to strains found in neonatal meningitis. Clinical Infectious Diseases 1993; 16: 412–416.
29.Johnson JR, Delavari P, O'Bryan TT. Escherichia coli O18:K1:H7 isolates from patients with acute cystitis and neonatal meningitis exhibit common phylogenetic origins and virulence factor profiles. Journal of Infectious Diseases 2001; 183: 425–434.
30.Tartof SY, et al. Analysis of a uropathogenic Escherichia coli clonal group by multilocus sequence typing. Journal of Clinical Microbiology 2005; 43: 5860–5864.
31.Manges AR, et al. The changing prevalence of drug-resistant Escherichia coli clonal groups in a community: evidence for community outbreaks of urinary tract infections. Epidemiology and Infection 2006; 134: 425–431.
32.Pitout JD, et al. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. Journal of Antimicrobial Chemotherapy 2005; 56: 52–59.
33.Oteo J, et al. Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. Journal of Clinical Microbiology 2006; 44: 2359–2366.
34.Mendonca N, et al. Spread of extended-spectrum beta-lactamase CTX-M-producing Escherichia coli clinical isolates in community and nosocomial environments in Portugal. Antimicrobial Agents and Chemotherapy 2007; 51: 1946–1955.
35.Vranes J, et al. Clonal dissemination of highly virulent extended-spectrum beta-lactamase-producing Escherichia coli strains isolated from the urine of non-hospitalised patients in Zagreb region. International Journal of Antimicrobial Agents 2008; 31 (Suppl. 1): S19–S24.
36.Lau SH, et al. Major uropathogenic Escherichia coli strain isolated in the northwest of England identified by multilocus sequence typing. Journal of Clinical Microbiology 2008; 46: 1076–1080.
37.Woodford N, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. Journal of Antimicrobial Chemotherapy 2004; 54: 735–743.
38.Pitout JD, et al. Virulence factors of Escherichia coli isolates that produce CTX-M-type extended-spectrum beta-lactamases. Antimicrobial Agents and Chemotherapy 2005; 49: 4667–4670.
39.Pitout JD, et al. Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates. Antimicrobial Agents and Chemotherapy 2007; 51: 1281–1286.
40.Nicolas-Chanoine MH, et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. Journal of Antimicrobial Chemotherapy 2008; 61: 273–281.
41.Karisik E, et al. Differential expression of CTX-M-15 Beta-lactamase between two major Escherichia coli strains responsible for outbreaks in the UK. Proceedings of 16th European Congress of Clincal Microbiology and Infectious Diseases, Nice, 2006.
42.Warren RE. Simultaneous, bi-clonal outbreak of urinary tract infection by E. coli O25 strains with CTX-M-15: community and hospital effects in two English health districts. Proceedings of 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, 2007.
43.Karisik E, et al. Virulence factors in Escherichia coli with CTX-M-15 and other extended-spectrum β-lactamases in the UK. Journal of Antimicrobial Chemotherapy 2008; 61: 54–58.
44.Blanco M, et al. Molecular epidemiology of Escherichia coli producing extended-spectrum β-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15. Journal of Antimicrobial Chemotherapy 2009; 63: 1135–1141.
45.Orskov I, et al. O, K, H and fimbrial antigens in Escherichia coli serotypes associated with pyelonephritis and cystitis. Scandinavian Journal of Infectious Diseases (Suppl.) 1982; 33: 18–25.
46.Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clinical Microbiology Reviews 1991; 4: 80–128.
47.Vosti KL. Infections of the urinary tract in women: a prospective, longitudinal study of 235 women observed for 1–19 years. Medicine 2002; 81: 369–387.
48.Mabeck CE, Orskov F, Orskov I. Escherichia coli serotypes and renal involvement in urinary-tract infection. Lancet 1971; 1: 1312–1314.
49.Freeman JT, Anderson DJ, Sexton DJ. Seasonal peaks in Escherichia coli infections: possible explanations and implications. Clinical Microbiology and Infection 2009; 15: 951–953.
50.Al-Hasan MN. Seasonal variation in Escherichia coli bloodstream infection: a population-based study. Clinical Microbiology and Infection 2009; 15: 947–950.
51.Anderson JE. Seasonality of symptomatic bacterial urinary infections in women. Journal of Epidemiology and Community Health 1983; 37: 286–290.
52.Prats G, et al. Cephalosporin-resistant Escherichia coli among summer camp attendees with salmonellosis. Emerging Infectious Diseases 2003; 9: 1273–1280.
53.Rantz LA. Serological grouping of Escherichia coli. Study in urinary tract infection. Archives of Internal Medicine 1962; 109: 37–42.
54.O'Keefe CM, Fairley KF. Escherichia coli in urinary tract infection: an epidemiological study. Medical Journal of Australia 1973; 2: 318–321.
55.Brede HD, et al. Escherichia coli serotypes associated with urinary tract infections in the Western Cape. South African Medical Journal 1974; 48: 261–263.
56.Wong WT, Bettelheim KA. Escherichia coli isolated from urinary tract infections in Hong Kong, 1969 to 1976. Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene A 1981; 251: 279–283.
57.Gransden WR, et al. Bacteremia due to Escherichia coli: a study of 861 episodes. Reviews of Infectious Diseases 1990; 12: 1008–1018.
58.McCabe WR, et al. Escherichia coli in bacteremia: K and O antigens and serum sensitivity of strains from adults and neonates. Journal of Infectious Diseases 2007; 138: 33–41.
59.Peddie BA, Bettelheim KA, Chereshsky AY. O and H serotypes of Escherichia coli isolated from urinary tract infections. Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene A 1981; 250: 47–51.
60.van den Bosch JF, et al. Virulence of Escherichia coli strains isolated from urine of patients with acute cystitis and from faeces of healthy women. Antonie Van Leeuwenhoek 1981; 47: 97–106.
61.Sandberg T, et al. Virulence of Escherichia coli in relation to host factors in women with symptomatic urinary tract infection. Journal of Clinical Microbiology 1988; 26: 1471–1476.
62.Otto G, et al. Virulence factors and pap genotype in Escherichia coli isolates from women with acute pyelonephritis, with or without bacteremia. Clinical Infectious Diseases 1993; 17: 448–456.
63.van den Bosch JF, et al. Virulence of urinary and faecal Escherichia coli in relation to serotype, haemolysis and haemagglutination. Journal of Hygiene 1982; 88: 567–577.
64.Ulleryd P, et al. Virulence characteristics of Escherichia coli in relation to host response in men with symptomatic urinary tract infection. Clinical Infectious Diseases 1994; 18: 579–584.
65.Olesen B, et al. A comparative study of nosocomial and community-acquired strains of Escherichia coli causing bacteraemia in a Danish University Hospital. Journal of Hospital Infections 1995; 31: 295–304.
66.Fule RP, Menon S, Saoji AM. Antibiotic resistance, haemagglutination type and haemolysin production in relation to serogroups of uropathogenic Escherichia coli. Indian Journal of Medical Research 1990; 91: 270–272.
67.Johnson JR, Brown JJ, Maslow JN. Clonal distribution of the three alleles of the Gal(alpha1-4)Gal-specific adhesin gene papG among Escherichia coli strains from patients with bacteremia. Journal of Infectious Diseases 1998; 177: 651–661.
68.Blanco M, et al. Virulence factors and O groups of Escherichia coli isolates from patients with acute pyelonephritis, cystitis and asymptomatic bacteriuria. European Journal of Epidemiology 1996; 12: 191–198.
69.Katouli M, et al. Virulence characteristics of Escherichia coli strains causing acute cystitis in young adults in Iran. Journal of Infection 2005; 50: 312–321.
70.Johnson JR, et al. Host-pathogen relationships among Escherichia coli isolates recovered from men with febrile urinary tract infection. Clinical Infectious Diseases 2005; 40: 813–822.
71.Johnson JR, et al. Bacterial characteristics in relation to clinical source of Escherichia coli isolates from women with acute cystitis or pyelonephritis and uninfected women. Journal of Clinical Microbiology 2005; 43: 6064–6072.
72.Andreu A, et al. Urovirulence determinants in Escherichia coli strains causing prostatitis. Journal of Infectious Diseases 1997; 176: 464–469.
73.Terai A, et al. Escherichia coli virulence factors and serotypes in acute bacterial prostatitis. International Journal of Urology 1997; 4: 289–294.
74.Johnson JR, et al. papG alleles of Escherichia coli strains causing first-episode or recurrent acute cystitis in adult women. Journal of Infectious Diseases 1998; 177: 97–101.
75.Olesen B, et al. Escherichia coli bacteraemia in patients with and without haematological malignancies: a study of strain characters and recurrent episodes. Journal of Infection 1998; 36: 93–100.
76.Ananias M, Yano T. Serogroups and virulence genotypes of Escherichia coli isolated from patients with sepsis. Brazilian Journal of Medical and Biological Research 2008; 41: 877–883.
77.Moher D, et al. Preferred Reporting Items for Systematic reviews and Meta-Analyses: the PRISMA Statement. PLoS Medicine 2009; 6: e1000097.